Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function : AAn immunohistochemical and functional study;Bedeutung von phosphodiesteraseisoenzymen in der kontrolle der humanen detrusormuskulatur : Eine immunhistochemische und funktionelle In-vitro-Studie

Urologe - Ausgabe A

Volumn 48, Issue 7, 2009, Pages 764-769

  Uckert S ^a   Sigl, K ^b   Waldkirch, E S ^a   Sandner, P ^c   Ulbrich, E ^c   Oelke, M ^a   Stief, C G ^b   Kuczyk, M A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Benign prostatic syndrome (BPS); Detrusor smooth muscle; Lower urinary tract symptomatology (LUTS); PDE5 inhibitors; Phosphodiesterase 5 (PDE5)

Indexed keywords

CARBACHOL; CYCLIC AMP; CYCLIC GMP; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; ROLIPRAM; SILDENAFIL; TADALAFIL; VARDENAFIL; VINPOCETINE;

ARTICLE; DETRUSOR MUSCLE; DOSE RESPONSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MUSCLE RELAXATION; MUSCLE TONE; PROTEIN EXPRESSION; SMOOTH MUSCLE;

HUMANS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; TISSUE DISTRIBUTION; URINARY BLADDER;

EID: 68349126778     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-009-1970-z     Document Type: Article

References (23)

1. Oelke M und der Arbeitskreis BPH der Deutschen Gesellschaft für Urologie (DGU) (2003) Leitlinien der Deutschen Urologen zur Diagnostik des benignen Prostatasyndroms. Urologe A 42: 584-590
2. Burnett AL, Maguire MP, Chamness SL et al (1995) Characterization and localization of nitric oxide synthase in the human prostate. Urology 45: 435-439
3. Bloch W, Klotz T, Loch C et al (1997) Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone and secretory function in the human prostate by nitric oxide. Prostate 33: 1-8
4. Hedlund P, Ekstrom P, Larsson B et al (1997) Heme oxygenase and NO synthase in the human prostate - relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 63: 115-126
5. Kedia G, Ückert S, Scheller F et al (2006) In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology 67: 1292-1297
6. Ückert S, Oelke M, Stief CG et al (2006) Immunohistochemical distribution of cAMP- and cGMPphosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49: 740-745
7. Takeda M, Tang R, Shapiro E et al (1995) Effects of nitric oxide on human and canine prostates. Urology 45: 440-446
8. McVary KT, Monnig W, Camps JL et al (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071-1077
9. McVary KT, Roehrborn CG, Kaminetsky JC et al (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177: 1401-1407
10. Stief CG, Porst H, Neuser D et al (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236-1244
11. Gülcer C, Tüzel E, Dogantekin E, Kiziltepe G (2008) Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int 80: 181-185
12. Truss MC, Ückert S, Stief CG et al (1996) Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle: I. Identification and characterization. Urol Res 24: 123-128
13. Filippi S, Morelli A, Sandner P et al (2007) Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148: 1019-1029
14. Truss MC, Ückert S, Stief CG et al (1996) Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle: II. Effect of various PDE-inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 24: 129-134
15. Truss MC, Stief CG, Ückert S et al (2000) Initial clinical experience with the selective phosphodiesterase (PDE) 1 isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 18: 439-443
16. Abrams PH, Griffiths DJ (1979) The assessment of prostatic obstruction from urodynamic measurements and from residual urine. BJU Int 51: 129-134
17. Oelke M, Höfner K, Wiese B et al (2002) Increase in detrusor wall thickness indicates bladder outlet obstruction. World J Urol 19: 443-452
18. Andersson KE, Appell R, Cardozo LD et al (1999) The pharmacological treatment of urinary incontinence. BJU Int 84: 923-947
19. Abrams PH, Khoury S, Wein A (1999) 1st International Consultation on Incontinence. Health Publications Ltd., Plymouth, UK
20. Hayes JS, Brunton LL (1982) Functional compartments of cyclic nucleotide action. J Cyclic Nucleotide Res 8: 1-16
21. Gillespie JL, Markering-van lttersum M, deVente J (2005) Expression of neuronal nitric oxide synthase (nNOS) and nitric oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder. Cell Tissue Res 321: 341-351
22. Bischoff E, Schramm M, Straub A et al (2003) BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide dependent penile erection. Urology 61: 464-467
23. Gacci M, del Popolo G, Macchiarella A et al (2007) Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 178: 2040-2043